sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Thy1ϵĤÔöÉúÐÔÉöÑ×¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÃÚÄòϵͳģ×Ó > Thy1ϵĤÔöÉúÐÔÉöÑ×¶¯ÎïÄ£×Ó

ǰÑÔ

ÉöСÇò¼²²¡(glomerular diseases)ÊDz¡Òò¡¢·¢²¡»úÖÆ¡¢ÁÙ´²ÌåÏÖ¡¢²¡Àí¸Ä±ä¡¢²¡³ÌºÍÔ¤ºó²»¾¡ÏàͬµÄÖ÷ÒªÀÛ¼°Ë«ÉöÉöСÇòµÄÒ»×é¼²²¡£¬¿É·ÖΪԭ·¢ÐÔ¡¢¼Ì·¢ÐÔºÍÒÅ´«ÐÔ¡£´ó¶¼ÉöСÇòÉöÑ×ÊÇÃâÒ߽鵼ÐÔÑ×Ö¢¼²²¡¡£Ò»Ñùƽ³£ÒÔΪ£¬ÃâÒß»úÖÆÊÇÉöСÇò²¡µÄʼ·¢»úÖÆ£¬ÉöСÇò¼²²¡¶¯ÎïÄ£×ÓÔÚ̽ÌÖ·¢²¡»úÖÆ¡¢²¡ÀíÀú³ÌÒÔ¼°ÁÙ´²ÖÎÁƵȷ½ÃæÊ©Õ¹Ö÷Òª×÷Óᣱ¾½ÚÖ÷ÒªÏÈÈÝÁËϵĤÔöÖ³ÐÔÉöСÇòÉöÑס¢Thy1ϵĤÔöÉúÐÔÉöÑס¢Ï¸Ð¡²¡±äÐÍÉö²¡¡¢IgAÉö²¡ÒÔ¼°ÉöСÇòÓ²»¯ÐÔÉö²¡¶¯ÎïÄ£×ӵĽ¨ÉèÒªÁìºÍÌØµã¡£

Thy1ϵĤÔöÉúÐÔÉöÑ×(mesangial proliferalive glomerulonephritis,MsPGN)Ä£×ÓΪ´óÊóÐØÏÙϸ°û¿¹ÌåÓÕ·¢µÄϵĤÔöÉúÐÔÉöÑ×Ä£×Ó£¬ÊÇÏÖÔÚÆÕ±éÓ¦Óò¢¹«ÈϽÏÁ¿µä·¶µÄÉöÑ×Ä£×Ó¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

Thy1Ϊ´óÊóÐØÏÙϸ°û·Ö½â¿¹Ô­£¬Thy1¿¹ÑªÇå¿ÉÖ±½ÓÓë´óÊóϵĤϸ°ûÍâò¿¹Ô­ÍŽἤ»î²¹ÌåÐγÉĤ¹¥»÷¸´ºÏÌ壬µ¼ÖÂϸ°ûÁѽ⣬´Ó¶øÒýÆðÊ£ÓàµÄϵĤϸ°ûÔöÉú¡£¾­ÆäÖØ¸´¹¥»÷ºó£¬ÏµÄ¤Ï¸°ûÔöÉúÄܽϳ¤Ê±¼äÒ»Á¬£¬×îÖÕÀÖ³ÉÓÕ·¢Thy1ϵĤÔöÉúÐÔÉöÑ×Ä£×Ó¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.ʵÑéÀú³Ì ¼ÒÍÿ¹´óÊóÐØÏÙϸ°û¿¹ÑªÇåµÄÖÆ±¸£º¿¨½éÃçÔ¤ÖÂÃôÐÂÎ÷À¼¸÷ÈËÍã¬14Ììºó¼ûÁ½²àÄNÎÑÁÜͶºÏÖ×´ó£¬×¢ÉäÐØÏÙϸ°û(1011/L£©Ó븥ÊÏÍêÈ«×ô¼Á¡£3ÖܺóͬÑù;¾¶ÔÙ´ÎÃâÒß¡£2Öܺ󾭶úÔµ¾²ÂöµÚ3´ÎÃâÒß¡£1ÖܲâЧ¼Û£¬Öª×ãºó¾±¶¯Âö·ÅѪ£¬ÍøÂçѪÇ壬¼ÒÍÿ¹ÑªÇå¾­´óÊó¸Î·ÛÎü¸½£¬-20¡æÉúÑÄ£¬Ê¹ÓÃǰ56¡æË®Ô¡30·ÖÖÓÃð»î²¹Ìå¡£

Ä£×ÓÖÆ±¸£ºÈ¡´óÊó(6~8ÖÜ£©Î²¾²Âö×¢Éä¼ÒÍÿ¹ÑªÇå(0.6ml/100g)£¬»®·ÖÓÚºó1Ìì¡¢3Ìì¡¢5Ìì¡¢7Ìì¡¢2 ÖÜ¡¢3ÖÜ¡¢4ÖܺÍ5ÖÜÕý·¨¶¯ÎȡÉöÔà×öÏìÓ¦¼ì²é¡£

2.Ö¸±ê¼ì²â Õý·¨Ç°¸ôÈÕÊÓ²ìÆäÄòÁ¿¡¢ÒûË®Á¿¡¢24СʱÄòÂѰ׶¨Á¿£¬½«ÉöÔಡÀíÇÐÆ¬¾ÙÐÐH&EȾɫ£¬¹â¾µÊÓ²ìÉöСÇòµÄ²¡Àíת±ä£¬Í¬Ê±¶Ôϸ°ûºËÔöÖ³¿¹Ô­(PCNA)¡¢α£­Æ½»¬¼¡¼¡¶¯ÂѰ×(α-SMA)¾ÙÐÐÃâÒßȾɫÊӲ죬²¢¼ÆÊýÉöСÇòϵĤÓкËϸ°û¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.Ò»Á¬4´Î×¢Éä¼ÒÍÿ¹ÑªÇ壬4Öܼ´¿ÉÀֳɵؽ¨ÉèThy1ϵĤÔöÉúÐÔÉöÑ×Ä£×Ó¡£

2.²¡±äÏÔ×Å£¬ÏµÄ¤»ùÖÊÔö¶àÏÔÖø£¬²¡±äÉöСÇòÌå»ýÔö´ó£¬µÚ1ÌìϵĤÏûÈÚ£¬ÉöСÇòÊýÏÔ×ÅïÔÌ­£¬µÚ3Ììϸ°û×îÏÈÔöÉú£¬µÚ7ÌìÏÔÖøÔöÌí²¢¿Éά³Öµ½µÚ5ÖÜ¡£

3.ÓÕµ¼28Ìì¡¢35Ììʱ£¬PCNA¡¢α-SMAÑôÐÔϸ°ûÔö¶àÇÒ²¡±äÒ»Á¬Ê±¼ä½Ï³¤¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

ÉöСÇòϵĤϸ°ûÔöÉúÒÔ¼°ÏµÄ¤»ùÖÊÔö¶àÊǶàÖÖÀàÐÍÉöÑ׳£¼ûµÄ²¡Àíת±ä£¬Ò²ÊÇÉöСÇòÓ²»¯µÄÔçÆÚ½×¶ÎÌØÕ÷¡£¸ÃÄ£×ÓÉöÑײ¡±äÏÔ×Å£¬ÏµÄ¤Ï¸°ûÔöÉúÏÔÖøÇÒÒ»Á¬±£´æ£¬ÏµÄ¤Ï¸°ûα-SMAÒ»Á¬ÑôÐÔ£¬ÅúעϵĤϸ°ûÒ»Ö±´¦ÓڻÔöÖ³½×¶Î£¬²¡±äÒ»Á¬Ô˶¯£¬¸üÇкÏÁÙ´²ÉÏËù¼ûµ½µÄÈËÀàϵĤÔöÉúÐÔÉöÑס£¸ÃÄ£×ÓʹÓø¥ÊÏÍêÈ«×ô¼ÁÔöÇ¿ÃâÒߣ¬Ëõ¶ÌÁËÔìģʱ¼ä£¬Ö¢×´µä·¶£¬ÊÇÏÖÔÚº£ÄÚÍ⹫ÈϵÄÑо¿ÏµÄ¤ÔöÖ³ÐÔÉöÑ×·¢²¡»úÖÆºÍ·ÀÖβ½·¥µÄÀíÏëÄ£×Ó¡£

 

²Î¿¼ÎÄÏ×£º

1.ÌÀÓ±£¬Â¦Ì½Ææ£¬³É²ÊÁª£¬µÈʵÑéÐÔIgAÉö²¡Ä£×ÓµÄˢУ®ÖÐɽ´óѧѧ±¨£¨Ò½Ñ§¿ÆÑ§°æ£©£¬2006,27 (2): 184-187

2.Î⺺Àû£¬Ëïΰ£®°¢Èá±ÈÐǽ¨ÉèÉö²¡Ä£×ӵįÀ¼Û£®ÖйúÖÐÒ½¼±Ö¢£¬2010,19 (2):290-191

3.ÕÅÀö·Ò£¬»ÆÎÄÕþ£¬ÖìС馣¬µÈ£®°¢Ã¹ËØÉö²¡ÉöСÇòÓ²»¯¶¯ÎïÄ£×ÓµÄÑо¿. ÖйúÖÐÎ÷ҽ͎áÉö²¡ÔÓÖ¾£¬2005,6 (4):195-199

4.Õſ˷Ç£¬ÕÅÁÁ£¬ÎâÐÛ·É£¬µÈ£®´óÊó¿¹Thy1ϵĤÔöÉúÐÔÉöСÇòÉöÑ×Ä£×Ó·¢²¡»úÖÆÌ½ÌÖ£®ËÄ´¨´óѧѧ±¨£¨Ò½Ñ§°æ£©£¬ 2004,35 (2): 188-190

5.³Â¹ãƽ£¬¹ù¹§ÒÀ£¬ÕÅԶ𣬵ȣ®´óÊóThy1¿¹ÑªÇåÖÆ±¸¼°ÏµÄ¤ÔöÉúÐÔÉöÑ×Ä£×ӵĽ¨É裮ÁÙ´²ÓëʵÑ鲡ÀíѧÔÓÖ¾£¬1996, 12 (3):241-243

6.»ÆÊ¤£¬ËïÁÖ£¬Ò¶Èθߣ¬µÈ£®Á½ÖÖϵĤÔöÖ³ÐÔÉöÑ×´óÊóÄ£×ӵĽ¨Éè½ÏÁ¿£®ÖйúʵÑ鶯Îïѧ±¨£¬2002, 10 (4): 236-238

7.Marquina R, Dfez MA,López-Hoyos M,el al. Inhibition of B cell death causes the development of an lgA nephropathy in(New Zealand white x C578L/6)F(l)-bel-2 transgenic mice. J lmmunol,2004,172(11):7177-7185

8.Zhang Z, Kundu GC, Yuan CJ, el al. Severe fibroneclin­deposit renal glomerular disease in mice lacking uteroglobin. Science, 1997,276(5317): 1408-1412

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÃÚÄòϵͳģ×Ó > Thy1ϵĤÔöÉúÐÔÉöÑ×¶¯ÎïÄ£×Ó
Thy1ϵĤÔöÉúÐÔÉöÑ×¶¯ÎïÄ£×Ó

ǰÑÔ

ÉöСÇò¼²²¡(glomerular diseases)ÊDz¡Òò¡¢·¢²¡»úÖÆ¡¢ÁÙ´²ÌåÏÖ¡¢²¡Àí¸Ä±ä¡¢²¡³ÌºÍÔ¤ºó²»¾¡ÏàͬµÄÖ÷ÒªÀÛ¼°Ë«ÉöÉöСÇòµÄÒ»×é¼²²¡£¬¿É·ÖΪԭ·¢ÐÔ¡¢¼Ì·¢ÐÔºÍÒÅ´«ÐÔ¡£´ó¶¼ÉöСÇòÉöÑ×ÊÇÃâÒ߽鵼ÐÔÑ×Ö¢¼²²¡¡£Ò»Ñùƽ³£ÒÔΪ£¬ÃâÒß»úÖÆÊÇÉöСÇò²¡µÄʼ·¢»úÖÆ£¬ÉöСÇò¼²²¡¶¯ÎïÄ£×ÓÔÚ̽ÌÖ·¢²¡»úÖÆ¡¢²¡ÀíÀú³ÌÒÔ¼°ÁÙ´²ÖÎÁƵȷ½ÃæÊ©Õ¹Ö÷Òª×÷Óᣱ¾½ÚÖ÷ÒªÏÈÈÝÁËϵĤÔöÖ³ÐÔÉöСÇòÉöÑס¢Thy1ϵĤÔöÉúÐÔÉöÑס¢Ï¸Ð¡²¡±äÐÍÉö²¡¡¢IgAÉö²¡ÒÔ¼°ÉöСÇòÓ²»¯ÐÔÉö²¡¶¯ÎïÄ£×ӵĽ¨ÉèÒªÁìºÍÌØµã¡£

Thy1ϵĤÔöÉúÐÔÉöÑ×(mesangial proliferalive glomerulonephritis,MsPGN)Ä£×ÓΪ´óÊóÐØÏÙϸ°û¿¹ÌåÓÕ·¢µÄϵĤÔöÉúÐÔÉöÑ×Ä£×Ó£¬ÊÇÏÖÔÚÆÕ±éÓ¦Óò¢¹«ÈϽÏÁ¿µä·¶µÄÉöÑ×Ä£×Ó¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

Thy1Ϊ´óÊóÐØÏÙϸ°û·Ö½â¿¹Ô­£¬Thy1¿¹ÑªÇå¿ÉÖ±½ÓÓë´óÊóϵĤϸ°ûÍâò¿¹Ô­ÍŽἤ»î²¹ÌåÐγÉĤ¹¥»÷¸´ºÏÌ壬µ¼ÖÂϸ°ûÁѽ⣬´Ó¶øÒýÆðÊ£ÓàµÄϵĤϸ°ûÔöÉú¡£¾­ÆäÖØ¸´¹¥»÷ºó£¬ÏµÄ¤Ï¸°ûÔöÉúÄܽϳ¤Ê±¼äÒ»Á¬£¬×îÖÕÀÖ³ÉÓÕ·¢Thy1ϵĤÔöÉúÐÔÉöÑ×Ä£×Ó¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.ʵÑéÀú³Ì ¼ÒÍÿ¹´óÊóÐØÏÙϸ°û¿¹ÑªÇåµÄÖÆ±¸£º¿¨½éÃçÔ¤ÖÂÃôÐÂÎ÷À¼¸÷ÈËÍã¬14Ììºó¼ûÁ½²àÄNÎÑÁÜͶºÏÖ×´ó£¬×¢ÉäÐØÏÙϸ°û(1011/L£©Ó븥ÊÏÍêÈ«×ô¼Á¡£3ÖܺóͬÑù;¾¶ÔÙ´ÎÃâÒß¡£2Öܺ󾭶úÔµ¾²ÂöµÚ3´ÎÃâÒß¡£1ÖܲâЧ¼Û£¬Öª×ãºó¾±¶¯Âö·ÅѪ£¬ÍøÂçѪÇ壬¼ÒÍÿ¹ÑªÇå¾­´óÊó¸Î·ÛÎü¸½£¬-20¡æÉúÑÄ£¬Ê¹ÓÃǰ56¡æË®Ô¡30·ÖÖÓÃð»î²¹Ìå¡£

Ä£×ÓÖÆ±¸£ºÈ¡´óÊó(6~8ÖÜ£©Î²¾²Âö×¢Éä¼ÒÍÿ¹ÑªÇå(0.6ml/100g)£¬»®·ÖÓÚºó1Ìì¡¢3Ìì¡¢5Ìì¡¢7Ìì¡¢2 ÖÜ¡¢3ÖÜ¡¢4ÖܺÍ5ÖÜÕý·¨¶¯ÎȡÉöÔà×öÏìÓ¦¼ì²é¡£

2.Ö¸±ê¼ì²â Õý·¨Ç°¸ôÈÕÊÓ²ìÆäÄòÁ¿¡¢ÒûË®Á¿¡¢24СʱÄòÂѰ׶¨Á¿£¬½«ÉöÔಡÀíÇÐÆ¬¾ÙÐÐH&EȾɫ£¬¹â¾µÊÓ²ìÉöСÇòµÄ²¡Àíת±ä£¬Í¬Ê±¶Ôϸ°ûºËÔöÖ³¿¹Ô­(PCNA)¡¢α£­Æ½»¬¼¡¼¡¶¯ÂѰ×(α-SMA)¾ÙÐÐÃâÒßȾɫÊӲ죬²¢¼ÆÊýÉöСÇòϵĤÓкËϸ°û¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.Ò»Á¬4´Î×¢Éä¼ÒÍÿ¹ÑªÇ壬4Öܼ´¿ÉÀֳɵؽ¨ÉèThy1ϵĤÔöÉúÐÔÉöÑ×Ä£×Ó¡£

2.²¡±äÏÔ×Å£¬ÏµÄ¤»ùÖÊÔö¶àÏÔÖø£¬²¡±äÉöСÇòÌå»ýÔö´ó£¬µÚ1ÌìϵĤÏûÈÚ£¬ÉöСÇòÊýÏÔ×ÅïÔÌ­£¬µÚ3Ììϸ°û×îÏÈÔöÉú£¬µÚ7ÌìÏÔÖøÔöÌí²¢¿Éά³Öµ½µÚ5ÖÜ¡£

3.ÓÕµ¼28Ìì¡¢35Ììʱ£¬PCNA¡¢α-SMAÑôÐÔϸ°ûÔö¶àÇÒ²¡±äÒ»Á¬Ê±¼ä½Ï³¤¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

ÉöСÇòϵĤϸ°ûÔöÉúÒÔ¼°ÏµÄ¤»ùÖÊÔö¶àÊǶàÖÖÀàÐÍÉöÑ׳£¼ûµÄ²¡Àíת±ä£¬Ò²ÊÇÉöСÇòÓ²»¯µÄÔçÆÚ½×¶ÎÌØÕ÷¡£¸ÃÄ£×ÓÉöÑײ¡±äÏÔ×Å£¬ÏµÄ¤Ï¸°ûÔöÉúÏÔÖøÇÒÒ»Á¬±£´æ£¬ÏµÄ¤Ï¸°ûα-SMAÒ»Á¬ÑôÐÔ£¬ÅúעϵĤϸ°ûÒ»Ö±´¦ÓڻÔöÖ³½×¶Î£¬²¡±äÒ»Á¬Ô˶¯£¬¸üÇкÏÁÙ´²ÉÏËù¼ûµ½µÄÈËÀàϵĤÔöÉúÐÔÉöÑס£¸ÃÄ£×ÓʹÓø¥ÊÏÍêÈ«×ô¼ÁÔöÇ¿ÃâÒߣ¬Ëõ¶ÌÁËÔìģʱ¼ä£¬Ö¢×´µä·¶£¬ÊÇÏÖÔÚº£ÄÚÍ⹫ÈϵÄÑо¿ÏµÄ¤ÔöÖ³ÐÔÉöÑ×·¢²¡»úÖÆºÍ·ÀÖβ½·¥µÄÀíÏëÄ£×Ó¡£

 

²Î¿¼ÎÄÏ×£º

1.ÌÀÓ±£¬Â¦Ì½Ææ£¬³É²ÊÁª£¬µÈʵÑéÐÔIgAÉö²¡Ä£×ÓµÄˢУ®ÖÐɽ´óѧѧ±¨£¨Ò½Ñ§¿ÆÑ§°æ£©£¬2006,27 (2): 184-187

2.Î⺺Àû£¬Ëïΰ£®°¢Èá±ÈÐǽ¨ÉèÉö²¡Ä£×ӵįÀ¼Û£®ÖйúÖÐÒ½¼±Ö¢£¬2010,19 (2):290-191

3.ÕÅÀö·Ò£¬»ÆÎÄÕþ£¬ÖìС馣¬µÈ£®°¢Ã¹ËØÉö²¡ÉöСÇòÓ²»¯¶¯ÎïÄ£×ÓµÄÑо¿. ÖйúÖÐÎ÷ҽ͎áÉö²¡ÔÓÖ¾£¬2005,6 (4):195-199

4.Õſ˷Ç£¬ÕÅÁÁ£¬ÎâÐÛ·É£¬µÈ£®´óÊó¿¹Thy1ϵĤÔöÉúÐÔÉöСÇòÉöÑ×Ä£×Ó·¢²¡»úÖÆÌ½ÌÖ£®ËÄ´¨´óѧѧ±¨£¨Ò½Ñ§°æ£©£¬ 2004,35 (2): 188-190

5.³Â¹ãƽ£¬¹ù¹§ÒÀ£¬ÕÅԶ𣬵ȣ®´óÊóThy1¿¹ÑªÇåÖÆ±¸¼°ÏµÄ¤ÔöÉúÐÔÉöÑ×Ä£×ӵĽ¨É裮ÁÙ´²ÓëʵÑ鲡ÀíѧÔÓÖ¾£¬1996, 12 (3):241-243

6.»ÆÊ¤£¬ËïÁÖ£¬Ò¶Èθߣ¬µÈ£®Á½ÖÖϵĤÔöÖ³ÐÔÉöÑ×´óÊóÄ£×ӵĽ¨Éè½ÏÁ¿£®ÖйúʵÑ鶯Îïѧ±¨£¬2002, 10 (4): 236-238

7.Marquina R, Dfez MA,López-Hoyos M,el al. Inhibition of B cell death causes the development of an lgA nephropathy in(New Zealand white x C578L/6)F(l)-bel-2 transgenic mice. J lmmunol,2004,172(11):7177-7185

8.Zhang Z, Kundu GC, Yuan CJ, el al. Severe fibroneclin­deposit renal glomerular disease in mice lacking uteroglobin. Science, 1997,276(5317): 1408-1412

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿